bluebird bio (NASDAQ:BLUE) – Equities researchers at SunTrust Banks upped their FY2019 earnings per share estimates for shares of bluebird bio in a research note issued on Thursday, April 19th. SunTrust Banks analyst E. Nash now expects that the biotechnology company will earn ($6.89) per share for the year, up from their prior forecast of ($6.97). SunTrust Banks has a “Buy” rating and a $232.00 price objective on the stock. SunTrust Banks also issued estimates for bluebird bio’s FY2020 earnings at ($5.05) EPS, FY2021 earnings at ($0.89) EPS and FY2022 earnings at $7.75 EPS.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The company had revenue of $4.17 million during the quarter, compared to the consensus estimate of $7.11 million. During the same period in the prior year, the business posted ($1.88) earnings per share. bluebird bio’s revenue for the quarter was up 169.0% compared to the same quarter last year.
A number of other brokerages have also recently commented on BLUE. BTIG Research raised their target price on bluebird bio to $250.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $250.00 target price on shares of bluebird bio in a report on Tuesday, March 13th. Janney Montgomery Scott began coverage on bluebird bio in a report on Wednesday, March 14th. They issued a “neutral” rating and a $220.00 target price on the stock. BidaskClub cut bluebird bio from a “strong-buy” rating to a “buy” rating in a report on Friday, March 16th. Finally, UBS began coverage on bluebird bio in a report on Friday, March 16th. They issued a “sell” rating on the stock. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $195.65.
Shares of bluebird bio stock opened at $170.50 on Monday. bluebird bio has a one year low of $74.45 and a one year high of $236.17. The firm has a market capitalization of $8,522.27, a P/E ratio of -22.11 and a beta of 2.16.
In other bluebird bio news, Director Mark Vachon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $214.38, for a total transaction of $1,286,280.00. Following the sale, the director now directly owns 7,000 shares of the company’s stock, valued at $1,500,660. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Susanna Gatti High sold 17,262 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total value of $3,381,798.42. Following the transaction, the chief operating officer now owns 28,512 shares of the company’s stock, valued at approximately $5,585,785.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 79,512 shares of company stock worth $15,051,218. Insiders own 3.90% of the company’s stock.
Several institutional investors have recently modified their holdings of BLUE. Meeder Asset Management Inc. grew its position in shares of bluebird bio by 2,110.3% during the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 612 shares in the last quarter. NuWave Investment Management LLC purchased a new position in shares of bluebird bio during the fourth quarter valued at about $135,000. Ladenburg Thalmann Financial Services Inc. grew its position in shares of bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 813 shares in the last quarter. D.A. Davidson & CO. purchased a new position in shares of bluebird bio during the fourth quarter valued at about $214,000. Finally, Quinn Opportunity Partners LLC purchased a new position in shares of bluebird bio during the fourth quarter valued at about $232,000.
ILLEGAL ACTIVITY NOTICE: “bluebird bio (BLUE) to Post FY2019 Earnings of ($6.89) Per Share, SunTrust Banks Forecasts” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/23/bluebird-bio-blue-to-post-fy2019-earnings-of-6-89-per-share-suntrust-banks-forecasts.html.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.